Creating unbiased and equitable access to the HD community to expedite key questions for research.
Date: Sunday, 15 September
Time: 8 a.m. – 12 p.m.
Location: Hilton, Strasbourg, France
Email at jenna@hdyo.org for more information!
As clinical research and trials are progressing with the aim of either preventing the development of HD or treating HD as early in life as possible, there is a growing need for industry partners, academic researchers, and regulators to rely on the advocacy communities to understand patients’ and families’ perspectives around these novel therapies and treatment paradigms. This is especially critical for understanding the different risks communities are willing to endure based upon the benefits possible with emerging treatments. In depth feedback cannot be collected in a simple format like a survey because there is a need to measure the community’s understanding around these complex topics first.
A round table format supports the need to engage the community in a meaningful conversation around broad risk-benefit considerations, which may be highly variable between individuals. In addition, HD is a generational disease with many serving as caregivers and future patients; we need to further understand how they would consider the risk-benefit balance both for themselves as well as for their loved ones. The community’s feedback on these general risk-benefit questions is essential to advancing therapeutic treatments into clinically asymptomatic patient populations. This forum is intended to engage as many partners as possible at one time on thematic considerations to help industry and research partners further develop studies, trials and advocacy efforts. Follow-up discussions may then be held to focus on specific development programs or therapies.
Pre-Meeting:
During Meeting:
Post-Meeting:
Pharmaceutical Companies – 5 000€
Researcher, Regulators or Additional Industry Participants – 250€
Advocacy Association, HD Community Members and Young Investigators – 50€